Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Importance of genetic factors in the etiology of atopic dermatitis: a twin study.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Management of asthma in adults: do the patients get what they need--and want?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. International severe asthma registry (ISAR): protocol for a global registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Airway hyperresponsiveness to mannitol improves in both type 2 high and type 2 low asthma after specialist management

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The six-gene expression signature in whole sampled sputum provides clinically feasible inflammatory phenotyping of asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Robert A Nathan
  • Hendrik Nolte
  • David S Pearlman
  • P04334 Study Investigators
  • Vibeke Backer
Vis graf over relationer
Asthma is a heterogeneous condition characterized by reduced lung function, chronic inflammation, and periodic asthma deteriorations. This study was performed to evaluate the effect of mometasone furoate (MF)/formoterol (F) combination, 200/10 microg, administered twice daily (b.i.d.) on asthma deteriorations and pulmonary function in patients with asthma uncontrolled on medium-dose inhaled corticosteroid (ICS). After 2- to 3-week open-label run-in with MF 200 microg b.i.d., patients (>or=12 years) were randomized to 26 weeks of treatment with MF/F 200/10 microg, MF 200 microg, F 10 microg, or placebo b.i.d. Coprimary end points were time to first asthma deterioration (MF/F versus F) and bronchodilation, assessed by the area under the curve of the change in forced expiratory volume in 1 second 0-12 hours (FEV(1) AUC(0-12h); MF/F versus MF). A total of 781 patients were randomized. Treatment with MF/F 200/10 microg reduced asthma deteriorations and clinically judged deteriorations (i.e., deterioration resulting in emergency treatment, hospitalization, or treatment with additional excluded asthma medication [i.e., systemic corticosteroids]). The proportion of patients experiencing asthma deteriorations was MF/F, 30.4%; MF, 33.9%; F, 54.0%; placebo, 55.6% (p <0.001, MF/F versus F and placebo). There was a sixfold reduction in clinically judged deteriorations with MF/F versus F and placebo (p <0.001). Lung function improved more rapidly with MF/F than MF and placebo. Mean change from baseline FEV(1) AUC(0-12h) at week 12 was MF/F, 11.7% versus MF, 5.7%; F, 8.5%; and placebo, 3.9% (p <0.001). Treatment-related AEs were rare and similar across groups. Treatment with MF/F 200/10 microg was effective in reducing the risk of asthma deteriorations. MF/F was safe and provided rapid and sustained bronchodilation in patients with asthma.
OriginalsprogEngelsk
TidsskriftAllergy and asthma proceedings : the official journal of regional and state allergy societies
Vol/bind31
Udgave nummer4
Sider (fra-til)269-79
Antal sider11
DOI
StatusUdgivet - 1 jul. 2010

ID: 32359884